ERBB2 and breast cancer: In an attempt to summarize these data, Van de Ven S. et al. conducted a meta-analysis of 32 significant studies that investigated the changes in ERα, PgR, and HER2 status in post- vs. pre-surgical BC samples in patients that received NAC or neoadjuvant trastuzumab-based biochemotherapy [103].